Needham & Company Reiterates Buy Rating, $48 Price Target on Xenon Pharmaceuticals (XENE) on New XEN1101 Data
Tweet Send to a Friend
Needham & Company analyst Serge Belanger reiterated a Buy rating and $48.00 price target on Xenon Pharmaceuticals (NASDAQ: XENE), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
